See It to Secure It: Why Unified Visibility Is the Backbone of Modern IT 
Where Bitcoin stands today and where the indicators point – 1, 3 and 6-month outlook 
Virtune launches Virtune Stablecoin Index ETP on Nasdaq Stockholm, Nasdaq Helsinki and Deutsche Börse Xetra Does Your Mask/Respirator Filter Live Viruses?
For the First Time Scientific Data From a Certified Canadian Laboratory Answers This Fundamental Question….
New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by…
Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency
With eight new configurations, cobas pro® integrated solutions offers labs greater flexibility to ramp up…
Bioasis Technologies Inc. Announces Warrant Extension and Repricing
NEW HAVEN, Conn., March 22, 2021 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the…
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to…
Verrica Announces Pricing of Public Offering of Common Stock
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA),…
Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
EDISON, N.J., March 22, 2021 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, “Hepion”), a clinical…
Blood Sugar Blaster Reviews – Diabetes Supplement launched
Blood Sugar Blaster is a sugar-regulating supplement that seeks to prevent the user from catching…
Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
Bagsværd, Denmark, 22 March 2021 – Novo Nordisk today announced that the US Food and…
Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes
Company announcement – No. 16 / 2021 Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon)…
Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021
FOSTER CITY, Calif., March 22, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation…
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)…
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and…
Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D.
SANTA MONICA, Calif., March 22, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a…
Verrica Announces Proposed Public Offering of Common Stock
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology…
ContraFect Corporation Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
YONKERS, N.Y., March 22, 2021 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
Roche provides update on tominersen programme in manifest Huntington’s disease
Dosing to stop in Phase III clinical study of tominersen following recommendation from an Independent…
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
— 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis…
PRA’s Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical Programs
Four-part, patient-focused toolkit is available for download at no cost and allows sponsors to identify…
Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021
–93% of all patients who enrolled as a responder to MYCAPSSA® maintained their biochemical response…